Steroid pioneer gets Heritage Foundation, BIO award
Drug Discovery | Influencers | By BioSpectrum Bureau | 2 Comment | 22 Apr, 2013
Singapore: Chemical Heritage Foundation (CHF) and Biotechnology Industry Organization (BIO) have selected Mexican steroi...Read more
Austrianova starts cell bank for cancer therapy
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 21 Mar, 2013
Singapore: Austrianova Singapore has established a research cell bank, the first step towards late-phase clinical trials...Read more
Takeda, Dainippon to market schizophrenia drug
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 13 Aug, 2013
Singapore: Japanese companies Dainippon Sumitomo Pharma and Takeda Pharmaceutical have obtained approval for marketing a...Read more
Astellas to pay $300 mn for cancer drug conjugates
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 05 Apr, 2013
Singapore: Japan's Astellas Pharma has collaborated with US-based Ambrx for the discovery and development of novel antib...Read more
Jubilant, Janssen expand drug discovery alliance
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 21 Feb, 2014
Singapore: Jubilant Biosys, a subsidiary of Bangalore-based Jubilant Life Sciences, has expanded its drug discovery alli...Read more
Patrys' 2nd group concludes treatment in Germany
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 10 Apr, 2013
Singapore: Patrys completed initial treatment of second group of three patients in its phase I/IIa PAT-SM6 multiple myel...Read more
AstraZeneca biologics R&D arm acquires Amplimmune
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 27 Aug, 2013
Singapore: AstraZeneca's global biologics R&D arm, MedImmune, plans to acquire Amplimmune, which is a US-based biolo...Read more
Biostar, Shaanxi Uni to co-develop liver cancer drug
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 07 Mar, 2014
Singapore: Biostar Pharmaceuticals, a China-based manufacturer and marketer of pharmaceutical and health supplement prod...Read more
Otsuka schizophrenia relapse gets FDA nod
Drug Discovery | Regulatory | By BioSpectrum Bureau | 1 Comment | 01 Mar, 2013
Singapore: Japan-based Otsuka Pharmaceutical and H Lundbeck have received US FDA approval for Abilify Maintena (aripipra...Read more
Novogen to develop new class of cancer drugs
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 09 Oct, 2013
Singapore: Australia-based Novogen has acquired a novel drug technology that will be developed as a potentially major cl...Read more
FDA issues complete response letter for XARELTO
Drug Discovery | Regulatory | By BioSpectrum Bureau | 1 Comment | 22 Jun, 2012
Singapore: US Food and Drug Administration (FDA) have issued a complete response letter regarding a supplemental New Dru...Read more
Sanofi to develop novel drugs for drug-resistant TB
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 25 Sep, 2012
Singapore: Sanofi and the Global Alliance for TB Drug Development (TB Alliance) entered a research collaboration to acce...Read more
Lupin aims high with a strong R&D focus
Drug Discovery | Analysis | By BioSpectrum Bureau | 0 Comment | 18 Jun, 2012
Lupin Pharmaceutical, which aims to be the best transnational pharmaceutical company in the world, stroked 10.64 percent...Read more
Phosphagenics appoints three new non-executive directors
Drug Discovery | Influencers | By BioSpectrum Bureau | 2 Comment | 04 Mar, 2014
Singapore: Australian drug delivery technology company Phosphagenics has appointed biotech industry veterans Mr Lawrence...Read more
MerLion completes phase I of finafloxacin study
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 08 Nov, 2012
Singapore: Following successful first-in-man phase I and two phase IIa clinical studies with the oral formulation of fin...Read more
Changing the paradigm of drug development
Drug Discovery | Opinion | By BioSpectrum Bureau | 2 Comment | 08 Feb, 2013
Recent promising data on drug approvals in 2011 shows that there were 35 new molecular entities (NME) approved by the FD...Read more
Medivir, Daewoong end hepatitis drug development
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 09 Sep, 2013
Singapore: Sweden-based Medivir has discontinued the development of its hepatitis B compound MIV-210 based on a joint de...Read more
Eisai reveals phase III results of breast cancer drug Halaven
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 10 Jul, 2012
Singapore: Eisai revealed its preliminary results from a recently completed phase III study of Halaven versus capecitabi...Read more